


# Stanford

---



## Hong Song, MD, PhD

Assistant Professor of Radiology (Nuclear Medicine)  
Radiology - Rad/Nuclear Medicine

### CLINICAL OFFICE (PRIMARY)

- **Diagnostic Radiology**

300 Pasteur Dr Rm S092

MC 5105

Stanford, CA 94305

**Tel** (650) 723-4527      **Fax** (650) 723-1909

### Bio

---

#### BIO

Hong Song received his MD from Tulane University School of Medicine and a Ph.D. in Chemical Engineering from Tulane University. He performed research in targeted radionuclide therapy as a postdoctoral fellow at the Johns Hopkins University. Following medical school, he joined Dual pathway Nuclear Medicine and Diagnostic Radiology residency at Stanford. His current research interests include PSMA PET in biochemically recurrent prostate cancer and DOTATATE PET in PRRT for neuroendocrine tumors.

#### CLINICAL FOCUS

- Nuclear Radiology

#### ACADEMIC APPOINTMENTS

- Assistant Professor - University Medical Line, Radiology - Rad/Nuclear Medicine
- Member, Bio-X
- Member, Stanford Cancer Institute

#### PROFESSIONAL EDUCATION

- Medical Education: Tulane University School of Medicine (2016) LA
- Board Certification: Diagnostic Radiology, American Board of Radiology (2023)
- Board Certification: Nuclear Medicine, American Board of Nuclear Medicine (2022)
- Residency: Stanford University Radiology Residency (2022) CA
- Internship: Tulane University Internal Medicine Residency (2017) LA

### Research & Scholarship

---

#### CLINICAL TRIALS

- A Study of Radiation Dosimetry, Safety, and Tolerability of Extended Lutetium (<sup>177</sup>Lu) Vipivotide Tetraxetan Treatment in Chemo-naïve Adults With Metastatic Castration-resistant Prostate Cancer: RADIOpharmaceutical DOSimetry Evaluation (RADIODOSE) Study, Recruiting

- Phase I/IIa Theranostic of <sup>64</sup>Cu-SAR-bisPSMA & <sup>67</sup>Cu-SAR-bisPSMA for ID & Tx of PSMA-Expressing mCRPC, Recruiting
- Phase III PET using <sup>64</sup>Cu-SAR-bisPSMA in High-Risk Prostate Cancer Prior to Radical Prostatectomy, Recruiting
- <sup>64</sup>Cu-SAR-BBN PET: Phase II in PSMA-Negative Biochemical Recurrence of Prostate Cancer, Not Recruiting
- Phase I Open-Label Multi-Center Study of [<sup>177</sup>Lu]Lu-FF58 in Selected Advanced Solid Tumors, Not Recruiting
- Phase I PSMA SSTR2 & GRPR Targeted Radioligand Therapy in Metastatic Neuroendocrine Prostate Cancer, Not Recruiting
- Phase I Study of [<sup>177</sup>Lu]Lu-NNS309 in Patients With Pancreatic, Lung, Breast and Colorectal Cancers, Not Recruiting
- Phase I/IIa <sup>177</sup>Lu-NeoB in Advanced Solid Tumors Known to Overexpress Gastrin-Releasing Peptide Receptor, Not Recruiting
- Phase III <sup>177</sup>Lu-PSMA-617 +/- Standard of Care in Metastatic Hormone Sensitive Prostate Cancer (mHSPC), Not Recruiting

## Publications

---

### PUBLICATIONS

- **[<sup>18</sup>F]F-AraG imaging reveals association between neuroinflammation and brown- and bone marrow adipose tissue.** *Communications biology*  
Levi, J., Guglielmetti, C., Henrich, T. J., Yoon, J. C., Gokhale, P. C., Reardon, D. A., Packiasamy, J., Huynh, L., Cabrera, H., Ruzevich, M., Blecha, J., Peluso, M. J., Huynh, et al  
2024; 7 (1): 793
- **Alpha and Beta Radiation for Theragnostics.** *PET clinics*  
Song, H., Sgouros, G.  
2024
- **Same-day post-therapy imaging with a new generation whole-body digital SPECT/CT in assessing treatment response to [<sup>177</sup>Lu]Lu-PSMA-617 in metastatic castration-resistant prostate cancer.** *European journal of nuclear medicine and molecular imaging*  
Song, H., Leonio, M. I., Ferri, V., Duan, H., Aparici, C. M., Davidzon, G., Franc, B. L., Moradi, F., Shah, J., Bergstrom, C. P., Fan, A. C., Shah, S., Khaki, et al  
2024
- **<sup>68</sup>Ga-RM2 PET-MRI versus MRI alone for evaluation of patients with biochemical recurrence of prostate cancer: a single-centre, single-arm, phase 2/3 imaging trial.** *The Lancet. Oncology*  
Duan, H., Moradi, F., Davidzon, G. A., Liang, T., Song, H., Loening, A. M., Vasanawala, S., Srinivas, S., Brooks, J. D., Hancock, S., Iagaru, A.  
2024
- **Real world outcomes in patients with metastatic castration-resistant prostate cancer (mCRPC) treated with lutetium-177-PSMA-vipivotide tetraxetan (Lu177-PVT)**  
Bergstrom, C. P., Song, H., Ruiz, S., Chien, J., Moore, K., Parikh, D., Shah, S., Fan, A. C., Srinivas, S., Iagaru, A., Khaki, A.  
LIPPINCOTT WILLIAMS & WILKINS.2024: 86
- **COMBAT: A study of <sup>64</sup>Cu-SAR-BBN and <sup>67</sup>Cu-SAR-BBN for identification and treatment of GRPr-expressing metastatic castrate-resistant prostate cancer.**  
Nordquist, L. T., Lengyelova, E., Almaguel, F., Mancini, B., Song, H., Armstrong, A. J., Zurita, A. J., Anderson, M., Parker, M., Miller, R. M., Iagaru, A.  
LIPPINCOTT WILLIAMS & WILKINS.2024: TPS247
- **Analysing the tumor transcriptome of prostate cancer to predict efficacy of Lu-PSMA therapy.** *Journal for immunotherapy of cancer*  
Handke, A., Kesch, C., Fendler, W. P., Telli, T., Liu, Y., Hakansson, A., Davicioni, E., Hughes, J., Song, H., Lueckerath, K., Herrmann, K., Hadaschik, B., Seifert, et al  
2023; 11 (10)
- **Modified PROMISE criteria for standardized interpretation of gastrin-releasing peptide receptor (GRPR)-targeted PET.** *European journal of nuclear medicine and molecular imaging*  
Duan, H., Davidzon, G. A., Moradi, F., Liang, T., Song, H., Iagaru, A.  
2023
- **Total and anatomically contextualized quantitative <sup>18</sup>F-DCFPyL PET at biochemical recurrence to predict subsequent biochemical progression free survival in patients with prostate cancer**  
Song, H., Sjostrand, K., Duan, H., Ferri, V., Aparici, C., Davidzon, G., Franc, B., Moradi, F., Anand, A., Iagaru, A.

LIPPINCOTT WILLIAMS & WILKINS.2023

- **SPECT at the speed of PET: a feasibility study of CZT-based whole-body SPECT/CT in the post 177Lu-DOTATATE and 177Lu-PSMA617 setting.** *European journal of nuclear medicine and molecular imaging*  
Song, H., Ferri, V., Duan, H., Aparici, C. M., Davidzon, G., Franc, B. L., Moradi, F., Nguyen, J., Shah, J., Iagaru, A.  
2023
- **64Cu-DOTATATE Uptake in a Pulmonary Hamartoma.** *Clinical nuclear medicine*  
Song, H., Guja, K. E., Yang, E. J., Guo, H. H.  
2023; 48 (1): 58-60
- **Biodistribution of a Mitochondrial Metabolic Tracer, [18F]F-AraG, in Healthy Volunteers.** *Molecular imaging*  
Levi, J., Duan, H., Yaghoubi, S., Packiasamy, J., Huynh, L., Lam, T., Shaikh, F., Behera, D., Song, H., Blecha, J., Jivan, S., Seo, Y., VanBrocklin, et al  
2022; 2022: 3667417
- **Results of First Interim Analysis of 68Ga-NeoB and 68Ga-PSMA R2 PET/MRI in Patients with Biochemically Recurrent Prostate Cancer**  
Duan, H., Song, H., Davidzon, G., Moradi, F., Iagaru, A.  
SOC NUCLEAR MEDICINE INC.2022
- **PSMA theragnostics for metastatic castration resistant prostate cancer.** *Translational oncology*  
Song, H., Guja, K. E., Iagaru, A.  
2022; 22: 101438
- **The other immuno-PET: Metabolic tracers in evaluation of immune responses to immune checkpoint inhibitor therapy for solid tumors.** *Frontiers in immunology*  
Levi, J., Song, H.  
2022; 13: 1113924
- **18F DCFPyL PET Acquisition, Interpretation and Reporting: Suggestions Post Food and Drug Administration Approval.** *Journal of nuclear medicine : official publication, Society of Nuclear Medicine*  
Song, H., Iagaru, A., Rowe, S. P.  
2021
- **PROSPECTIVE STUDY OF (68)GA-RM2 PET/MRI IN PATIENTS WITH BIOCHEMICALLY RECURRENT PROSTATE CANCER AND NEGATIVE CONVENTIONAL IMAGING**  
Baratto, L., Song, H., Duan, H., Moradi, F., Davidzon, G., Iagaru, A.  
LIPPINCOTT WILLIAMS & WILKINS.2021: E1178
- **PROSPECTIVE EVALUATION OF F-18-DCFpyL PET/CT IN BIOCHEMICALLY RECURRENT PROSTATE CANCER: ANALYSIS OF F-18-DCFpyL UPTAKE IN POSSIBLE EXTRA-PELVIC OLIGOMETASTASES**  
Song, H., Nguyen, J., Moradi, F., Aparici, C., Franc, B., Davidzon, G., Iagaru, A.  
LIPPINCOTT WILLIAMS & WILKINS.2021: E1177-E1178
- **PSMA- and GRPR-targeted PET: Results from 50 Patients with Biochemically Recurrent Prostate Cancer.** *Journal of nuclear medicine : official publication, Society of Nuclear Medicine*  
Baratto, L., Song, H., Duan, H., Hatami, N., Bagshaw, H., Buyyounouski, M., Hancock, S., Shah, S. A., Srinivas, S., Swift, P., Moradi, F., Davidzon, G. A., Iagaru, et al  
2021
- **18F-FDG PET/CT for Evaluation of Post-Transplant Lymphoproliferative Disorder (PTLD).** *Seminars in nuclear medicine*  
Song, H., Guja, K. E., Iagaru, A.  
2021
- **Prospective Evaluation in an Academic Center of 18F-DCFpyL PET/CT in Biochemically Recurrent Prostate Cancer: A Focus on Localizing Disease and Changes in Management.** *Journal of nuclear medicine : official publication, Society of Nuclear Medicine*  
Song, H., Harrison, C., Duan, H., Guja, K., Hatami, N., Franc, B., Moradi, F., Mari Aparici, C., Davidzon, G., Iagaru, A.  
2019
- **Diagnostic 123I Whole Body Scan Prior to Ablation of Thyroid Remnant in Patients With Papillary Thyroid Cancer: Implications for Clinical Management** *CLINICAL NUCLEAR MEDICINE*  
Song, H., Mosci, C., Akatsu, H., Basina, M., Dosiou, C., Iagaru, A.

2018; 43 (10): 705–9

- **Effective treatment of ductal carcinoma in situ with a HER-2- targeted alpha-particle emitting radionuclide in a preclinical model of human breast cancer.** *Oncotarget*  
Yoshida, T., Jin, K., Song, H., Park, S., Huso, D. L., Zhang, Z., Liangfeng, H., Zhu, C., Bruchertseifer, F., Morgenstern, A., Sgouros, G., Sukumar, S.  
2016; 7 (22): 33306-15
- **Redefining relative biological effectiveness in the context of the EQDX formalism: implications for alpha-particle emitter therapy.** *Radiation research*  
Hobbs, R. F., Howell, R. W., Song, H., Baechler, S., Sgouros, G.  
2014; 181 (1): 90-8
- **Targeting aberrant DNA double-strand break repair in triple-negative breast cancer with alpha-particle emitter radiolabeled anti-EGFR antibody.** *Molecular cancer therapeutics*  
Song, H., Hedayati, M., Hobbs, R. F., Shao, C., Bruchertseifer, F., Morgenstern, A., Deweese, T. L., Sgouros, G.  
2013; 12 (10): 2043-54
- **Radiobiologic optimization of combination radiopharmaceutical therapy applied to myeloablative treatment of non-Hodgkin lymphoma.** *Journal of nuclear medicine : official publication, Society of Nuclear Medicine*  
Hobbs, R. F., Wahl, R. L., Frey, E. C., Kasamon, Y., Song, H., Huang, P., Jones, R. J., Sgouros, G.  
2013; 54 (9): 1535-42
- **A nephron-based model of the kidneys for macro-to-micro  $\alpha$ -particle dosimetry.** *Physics in medicine and biology*  
Hobbs, R. F., Song, H., Huso, D. L., Sundel, M. H., Sgouros, G.  
2012; 57 (13): 4403-24
- **A bone marrow toxicity model for  $^{223}\text{Ra}$  alpha-emitter radiopharmaceutical therapy.** *Physics in medicine and biology*  
Hobbs, R. F., Song, H., Watchman, C. J., Bolch, W. E., Aksnes, A. K., Ramdahl, T., Flux, G. D., Sgouros, G.  
2012; 57 (10): 3207-22
- **Trafficking of High Avidity HER-2/neu-Specific T Cells into HER-2/neu-Expressing Tumors after Depletion of Effector/Memory-Like Regulatory T Cells** *PLOS ONE*  
Weiss, V. L., Lee, T. H., Song, H., Kouo, T. S., Black, C. M., Sgouros, G., Jaffee, E. M., Armstrong, T. D.  
2012; 7 (2): e31962
- **Tumor dosimetry and response for  $^{153}\text{Sm}$ -ethylenediamine tetramethylene phosphonic acid therapy of high-risk osteosarcoma.** *Journal of nuclear medicine : official publication, Society of Nuclear Medicine*  
Senthamizchelvan, S., Hobbs, R. F., Song, H., Frey, E. C., Zhang, Z., Armour, E., Wahl, R. L., Loeb, D. M., Sgouros, G.  
2012; 53 (2): 215-24
- **Modelling and dosimetry for alpha-particle therapy.** *Current radiopharmaceuticals*  
Sgouros, G., Hobbs, R. F., Song, H.  
2011; 4 (3): 261-5
- **Radioimmunotherapy of solid tumors: searching for the right target.** *Current drug delivery*  
Song, H., Sgouros, G.  
2011; 8 (1): 26-44
- **Immunoliposomal delivery of  $^{213}\text{Bi}$  for alpha-emitter targeting of metastatic breast cancer.** *Cancer research*  
Lingappa, M., Song, H., Thompson, S., Bruchertseifer, F., Morgenstern, A., Sgouros, G.  
2010; 70 (17): 6815-23
- **MIRD Pamphlet No. 22 (abridged): radiobiology and dosimetry of alpha-particle emitters for targeted radionuclide therapy.** *Journal of nuclear medicine : official publication, Society of Nuclear Medicine*  
Sgouros, G., Roeske, J. C., McDevitt, M. R., Palm, S., Allen, B. J., Fisher, D. R., Brill, A. B., Song, H., Howell, R. W., Akabani, G., Bolch, W. E., Brill, A. B., Fisher, et al  
2010; 51 (2): 311-28
- **Radioimmunotherapy of breast cancer metastases with alpha-particle emitter  $^{225}\text{Ac}$ : comparing efficacy with  $^{213}\text{Bi}$  and  $^{90}\text{Y}$ .** *Cancer research*  
Song, H., Hobbs, R. F., Vajravelu, R., Huso, D. L., Esaias, C., Apostolidis, C., Morgenstern, A., Sgouros, G.

2009; 69 (23): 8941-8

- **An immunotolerant HER-2/neu transgenic mouse model of metastatic breast cancer.** *Clinical cancer research : an official journal of the American Association for Cancer Research*  
Song, H., Shahverdi, K., Huso, D. L., Wang, Y., Fox, J. J., Hobbs, R. F., Gimi, B., Gabrielson, K. L., Pomper, M. G., Tsui, B. M., Bhujwala, Z., Reilly, R. T., Sgouros, et al  
2008; 14 (19): 6116-24
- **<sup>213</sup>Bi (alpha-emitter)-antibody targeting of breast cancer metastases in the neu-N transgenic mouse model.** *Cancer research*  
Song, H., Shahverdi, K., Huso, D. L., Esaias, C., Fox, J., Liedy, A., Zhang, Z., Reilly, R. T., Apostolidis, C., Morgenstern, A., Sgouros, G.  
2008; 68 (10): 3873-80
- **Antibody association with HER-2/neu-targeted vaccine enhances CD8 T cell responses in mice through Fc-mediated activation of DCs.** *The Journal of clinical investigation*  
Kim, P. S., Armstrong, T. D., Song, H., Wolpoe, M. E., Weiss, V., Manning, E. A., Huang, L. Q., Murata, S., Sgouros, G., Emens, L. A., Reilly, R. T., Jaffee, E. M.  
2008; 118 (5): 1700-11
- **Cancer stem cell targeting using the alpha-particle emitter, <sup>213</sup>Bi: mathematical modeling and feasibility analysis.** *Cancer biotherapy & radiopharmaceuticals*  
Sgouros, G., Song, H.  
2008; 23 (1): 74-81
- **Three-dimensional radiobiologic dosimetry: application of radiobiologic modeling to patient-specific 3-dimensional imaging-based internal dosimetry.** *Journal of nuclear medicine : official publication, Society of Nuclear Medicine*  
Prideaux, A. R., Song, H., Hobbs, R. F., He, B., Frey, E. C., Ladenson, P. W., Wahl, R. L., Sgouros, G.  
2007; 48 (6): 1008-16
- **Therapeutic potential of <sup>90</sup>Y- and <sup>131</sup>I-labeled anti-CD20 monoclonal antibody in treating non-Hodgkin's lymphoma with pulmonary involvement: a Monte Carlo-based dosimetric analysis.** *Journal of nuclear medicine : official publication, Society of Nuclear Medicine*  
Song, H., Du, Y., Sgouros, G., Prideaux, A., Frey, E., Wahl, R. L.  
2007; 48 (1): 150-7
- **Lung dosimetry for radioiodine treatment planning in the case of diffuse lung metastases.** *Journal of nuclear medicine : official publication, Society of Nuclear Medicine*  
Song, H., He, B., Prideaux, A., Du, Y., Frey, E., Kasecamp, W., Ladenson, P. W., Wahl, R. L., Sgouros, G.  
2006; 47 (12): 1985-94
- **Lung toxicity in radioiodine therapy of thyroid carcinoma: development of a dose-rate method and dosimetric implications of the 80-mCi rule.** *Journal of nuclear medicine : official publication, Society of Nuclear Medicine*  
Sgouros, G., Song, H., Ladenson, P. W., Wahl, R. L.  
2006; 47 (12): 1977-84
- **Liposome-mediated radiotherapeutics within avascular tumor spheroids: comparative dosimetry study for various radionuclides, liposome systems, and a targeting antibody.** *Journal of nuclear medicine : official publication, Society of Nuclear Medicine*  
Emfietzoglou, D., Kostarelos, K., Papakostas, A., Yang, W. H., Ballangrud, A., Song, H., Sgouros, G.  
2005; 46 (1): 89-97
- **Spatial composition of prostate cancer spheroids in mixed and static cultures.** *Tissue engineering*  
Song, H., David, O., Clejan, S., Giordano, C. L., Pappas-Lebeau, H., Xu, L., O'Connor, K. C.  
2004; 10 (7-8): 1266-76
- **Restructuring dynamics of DU 145 and LNCaP prostate cancer spheroids.** *In vitro cellular & developmental biology. Animal*  
Song, H., Jain, S. K., Enmon, R. M., O'Connor, K. C.  
2004; 40 (8-9): 262-7
- **Monte Carlo simulation of LNCaP human prostate cancer cell aggregation in liquid-overlay culture.** *Biotechnology progress*  
Song, H., O'Connor, K. C., Lacks, D. J., Enmon, R. M., Jain, S. K.  
2003; 19 (6): 1742-9
- **Extracellular matrix substrata alter adipocyte yield and lipogenesis in primary cultures of stromal-vascular cells from human adipose.** *Biotechnology letters*

O'Connor, K. C., Song, H., Rosenzweig, N., Jansen, D. A.  
2003; 25 (23): 1967-72

- **Aggregation kinetics of well and poorly differentiated human prostate cancer cells.** *Biotechnology and bioengineering*  
Enmon, R. M., O'Connor, K. C., Song, H., Lacks, D. J., Schwartz, D. K.  
2002; 80 (5): 580-8